A body-shaped lumbar-sacral support for improving car-seat comfort.

BACKGROUND: Nowadays, the ergonomic study of the driving position is a critical aspect of automotive design. Indeed, due to the rising needs on the market, one focus for car industries is to improve the perceived comfort related to the cars' interior. Driving a car for a prolonged time could cause complaints in some body-regions, especially in the lumbar-sacral area. Thus, special lumbar-sacral supports for driver seat has been proposed for reducing this kind of complaints. OBJECTIVE: Development of two virtual and physical models of lumbar-sacral support for improving both the lumbar/sacral and overall perceived comfort while driving. METHODS: Two prototypes of lumbar/sacral support have been realized: the first one was integrated into the seat, and the second one was shaped as a removable pillow (removable support). Fifty participants were asked to rate the perceived comfort in lab tests performed on a seating-buck by comparing three configurations (5 min each): a standard seat, seat with the removable support, seat with integrated support. Subjective data (by questionnaires) and objective data (interface pressure between backrest and driver) have been acquired and statistically processed. In addition, real driving tests have been performed to test the actual performance of the removable support in term of perceived comfort comparing it with the standard seat. RESULTS: Statistical correlations between subjective and objective data showed interesting results in comfort improvement through the adopted solutions. Real driving tests showed an improvement in comfort perception with the lumbar-sacral support towards the standard seat. CONCLUSIONS: Thanks to the virtual prototyping and the application of previous knowledge, coming from literature and experience, a solution for improving the overall comfort and reduce the lumbar/sacral pain while driving has been developed, tested, and assessed.

Biliverdin protects against liver ischemia reperfusion injury in swine.

Ischemia reperfusion injury (IRI) in organ transplantation remains a serious and unsolved problem. Organs that undergo significant damage during IRI, function less well immediately after reperfusion and tend to have more problems at later times when rejection can occur. Biliverdin has emerged as an agent that potently suppress IRI in rodent models. Since the use of biliverdin is being developed as a potential therapeutic modality for humans, we tested the efficacy for its effects on IRI of the liver in swine, an accepted and relevant pre-clinical animal model. Administration of biliverdin resulted in rapid appearance of bilirubin in the serum and significantly suppressed IRI-induced liver dysfunction as measured by multiple parameters including urea and ammonia clearance, neutrophil infiltration and tissue histopathology including hepatocyte cell death. Taken together, our findings, in a large animal model, provide strong support for the continued evaluation of biliverdin as a potential therapeutic in the clinical setting of transplantation of the liver and perhaps other organs.

Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis.

BACKGROUND: A large number of renal cancer patients shows poor or partial response to chemotherapy and the mechanisms have not been still understood. Multi-drug resistance is the principal mechanism by which many cancers develop resistance to chemotherapic drugs. The role of the multi-drug resistant transporter (MDR-1/P-glycoprotein), the gene product of MDR-1, and that one of the so-called multi-drug resistance associated protein (MRP), two energy-dependent efflux pumps, are commonly known to confer drug resistance. We studied MDR-1 expression in selected cases of renal cell carcinoma (RCC), clear cell type, with long-term follow-up, in order to establish its prognostic role and its possible contribution in the choice of post-surgical therapy. METHODS: MDR-1 has been studied by standard LSAB-HRP immunohistochemical technique, in paraffin embedded RCC samples. Protein expression has been compared to clinical and histopathological data and to disease specific survival of RCC patients, by Kaplan-Meier curve and Cox multivariate regression analyses. RESULTS: Two groups of RCCs were obtained by esteeming MDR-1 expression and disease specific survival (obtained with Kaplan-Meier curve and Cox multivariate regression analyses): the first one presents low or absent MDR-1 expression and good survival; the second one is characterized by high MDR-1 expression and significant poor outcome (p < 0.05). Afterwards, we have found disease specific survival, adjusted for stages and independent of therapy: this difference of survival rates was statistically significant (p < 0.05). Stage adjusted disease specific survival rate, according to MDR-1 expression and therapy in patients affected by RCC in early stage (stage I), has revealed that the group of patients with high MDR-1 expression and without adjuvant therapy showed poor survival (p < 0.05). Cox multivariate regression analysis has confirmed that, in our cohort of RCC (clear cell type) patients, the strong association between MDR-1 and worse outcome is independent not only of the adjuvant therapy, but also of the other prognostic parameters (p < 0.05). CONCLUSION: In our opinion, the results of this study well prove the relationship between MDR-1 expression and worse clinical prognosis in RCC, because MDR-1 over-expressing RCCs can be considered a group of tumours with a more aggressive behavior. This finding outlines a possible role of MDR-1 as prognostic factor, dependent and independent of multidrug resistance. These results could be useful to predict cancer evolution and to choose the appropriate treatment: this is another step that can stimulate further promising and interesting investigations on broader study population.